Skip to main content
. Author manuscript; available in PMC: 2014 Jan 19.
Published in final edited form as: Mol Pharm. 2012 Jul 19;9(8):2339–2349. doi: 10.1021/mp300277f

Figure 5.

Figure 5

Ex vivo imaging and biodistribution studies. A. Ex vivo bioluminescence imaging (BLI), near-infrared fluorescence (NIRF), and positron emission tomography (PET) imaging of major organs at 48 h post-injection of each tracer. Images are representative of 4 mice per group. T: fLuc-4T1 tumor-bearing lung, L: liver, B1: blood, H: heart, K: kidney, B2: bone, S: spleen, M: muscle. B. Biodistribution of 89Zr-Df-TRC105-800CW or 89Zr-Df-cetuximab-800CW in fLuc-4T1 tumor-bearing mice at 48 h post-injection. C. Biodistribution in fLuc-4T1 tumor-bearing mice at 48 h post-injection of 89Zr-Df-TRC105-800CW or 89Zr-Df-TRC105-800CW after a blocking dose of TRC105. n = 4.